Brian Skorney
Stock Analyst at Baird
(4.01)
# 584
Out of 5,042 analysts
117
Total ratings
50%
Success rate
12.98%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Outperform | $10 → $16 | $14.19 | +12.76% | 3 | Oct 20, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $43.50 | +42.53% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $17.20 | +202.33% | 4 | Aug 12, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $30 → $35 | $24.01 | +45.77% | 12 | Jul 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $67.16 | +80.17% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $22.58 | +41.72% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $154.27 | +65.29% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $651.80 | -9.94% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $72.65 | -24.29% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $119.79 | -16.52% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $16.36 | +83.37% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $1.15 | +334.78% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $10.93 | +82.98% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.75 | +426.32% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $298.43 | -27.96% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $143.21 | +25.69% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $10.01 | +179.72% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $12.77 | +205.40% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $41.92 | +50.29% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $425.57 | -23.63% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $24.68 | -59.48% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $3.94 | +6,752.79% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.67 | +28.48% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.49 | +20,034.23% | 3 | May 7, 2018 |
Alto Neuroscience
Oct 20, 2025
Maintains: Outperform
Price Target: $10 → $16
Current: $14.19
Upside: +12.76%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $43.50
Upside: +42.53%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $17.20
Upside: +202.33%
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30 → $35
Current: $24.01
Upside: +45.77%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $67.16
Upside: +80.17%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $22.58
Upside: +41.72%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $154.27
Upside: +65.29%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $651.80
Upside: -9.94%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $72.65
Upside: -24.29%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $119.79
Upside: -16.52%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $16.36
Upside: +83.37%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $1.15
Upside: +334.78%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $10.93
Upside: +82.98%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $4.75
Upside: +426.32%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $298.43
Upside: -27.96%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $143.21
Upside: +25.69%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $10.01
Upside: +179.72%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $12.77
Upside: +205.40%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $41.92
Upside: +50.29%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $425.57
Upside: -23.63%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $24.68
Upside: -59.48%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $3.94
Upside: +6,752.79%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.67
Upside: +28.48%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.49
Upside: +20,034.23%